CN Patent

CN110563644A — 一种仑伐替尼甲磺酸盐的新晶型

Assigned to Beijing Saisiyuan Biomedical Technology Co Ltd · Expires 2019-12-13 · 6y expired

What this patent protects

本发明公开了一种仑伐替尼甲磺酸盐的新晶型,该新晶型使用Cu‑Ka射线进行测定的X‑射线粉末衍射图谱中,至少包含以下特征峰:衍射角2θ值为4.19±0.2°、10.15±0.2°、12.40±0.2°、18.93±0.2°、22.05±0.2°和29.26±0.2°;所得的新晶型的溶解性和稳定性好,适合工业化生产。此外,本发明还提供所述新晶型的制备方法和药用组合物。

USPTO Abstract

本发明公开了一种仑伐替尼甲磺酸盐的新晶型,该新晶型使用Cu‑Ka射线进行测定的X‑射线粉末衍射图谱中,至少包含以下特征峰:衍射角2θ值为4.19±0.2°、10.15±0.2°、12.40±0.2°、18.93±0.2°、22.05±0.2°和29.26±0.2°;所得的新晶型的溶解性和稳定性好,适合工业化生产。此外,本发明还提供所述新晶型的制备方法和药用组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN110563644A
Jurisdiction
CN
Classification
Expires
2019-12-13
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Saisiyuan Biomedical Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.